UBS’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$11.4M Buy
78,026
+23,312
+43% +$3.6M 0.01% 1347
2014
Q2
$9.14M Buy
54,714
+21,712
+66% +$3.86M 0.01% 1451
2014
Q1
$6.55M Buy
33,002
+1,989
+6% +$375K 0.01% 1599
2013
Q4
$5.92M Sell
31,013
-7,404
-19% -$1.38M 0.01% 1707
2013
Q3
$6.5M Buy
38,417
+7,282
+23% +$1.13M 0.01% 1487
2013
Q2
$4.72M Buy
+31,135
New +$4.41M 0.01% 1677

Other funds holding CLB

UBS's CLB Position: Q3 2014 in Review

UBS increased its Core Laboratories (CLB) stake by 43% in Q3 2014, buying an estimated $3.6M and bringing the position to 78,026 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #1347.

UBS first reported a position in CLB in Q2 2013 and has held it in 6 quarters since. 344 funds tracked by Wall St. Rank hold CLB as of Q3 2014.

  • UBS held 78,026 shares of Core Laboratories worth $11.4M as of Q3 2014.
  • UBS bought 23,312 Core Laboratories shares in Q3 2014, an estimated $3.6M.
  • Core Laboratories made up 0.01% of UBS's portfolio in Q3 2014, its #1347 holding.
  • UBS first reported a position in Core Laboratories in Q2 2013 and has held it in 6 quarters since.
  • 344 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.